Editorial
doi: 10.1200/JCO.2005.04.8801.
Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?
- PMID: 16574996
- DOI: 10.1200/JCO.2005.04.8801
Item in Clipboard
Editorial
Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?
J Clin Oncol.
.
No abstract available
Comment on
-
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.J Clin Oncol. 2006 Apr 1;24(10):1491-8. doi: 10.1200/JCO.2005.02.7458. J Clin Oncol. 2006. PMID: 16574998 Clinical Trial.
Similar articles
-
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.J Clin Oncol. 2006 Apr 1;24(10):1491-8. doi: 10.1200/JCO.2005.02.7458. J Clin Oncol. 2006. PMID: 16574998 Clinical Trial.
-
Challenges of evaluating the cardiac effects of anticancer agents.Clin Cancer Res. 2006 Jul 1;12(13):3871-4. doi: 10.1158/1078-0432.CCR-06-1017. Clin Cancer Res. 2006. PMID: 16818679 Review. No abstract available.
-
Anaphylactic reaction to etoposide phosphate.Pediatr Blood Cancer. 2012 Oct;59(4):765. doi: 10.1002/pbc.24183. Epub 2012 Apr 22. Pediatr Blood Cancer. 2012. PMID: 22522419 No abstract available.
-
Persistent thrombocytopenia during melanoma treatment with fotemustine.Melanoma Res. 2006 Dec;16(6):543-4. doi: 10.1097/CMR.0b013e3280103e18. Melanoma Res. 2006. PMID: 17119456
-
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.Oncologist. 2009 Jun;14(6):612-20. doi: 10.1634/theoncologist.2008-0287. Epub 2009 May 27. Oncologist. 2009. PMID: 19474164 Review.
Cited by
-
Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy.Small. 2014 Feb 12;10(3):566-75, 417. doi: 10.1002/smll.201301456. Epub 2013 Aug 27. Small. 2014. PMID: 24038954 Free PMC article.
-
Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.Cancer Res. 2010 Sep 1;70(17):6902-12. doi: 10.1158/0008-5472.CAN-10-1440. Epub 2010 Jul 27. Cancer Res. 2010. PMID: 20663911 Free PMC article.
-
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients.Br J Cancer. 2012 Jun 26;107(1):37-42. doi: 10.1038/bjc.2012.233. Epub 2012 May 29. Br J Cancer. 2012. PMID: 22644293 Free PMC article. Clinical Trial.
-
Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.J Natl Cancer Inst. 2010 Jan 6;102(1):14-25. doi: 10.1093/jnci/djp440. Epub 2009 Dec 10. J Natl Cancer Inst. 2010. PMID: 20007921 Free PMC article. Review.
-
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.Cancer Chemother Pharmacol. 2011 Apr;67(4):751-64. doi: 10.1007/s00280-010-1372-3. Epub 2010 Jun 3. Cancer Chemother Pharmacol. 2011. PMID: 20521052 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
